Fatty acid synthase inhibitors and methods of use thereof

TW202641514APending Publication Date: 2026-10-16BLUEJAY THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114150296
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-12-02
Filing Date
2025-12-19
Publication Date
2026-10-16

Smart Images

  • Figure TWG2TA001080767_001
    Figure TWG2TA001080767_001
  • Figure TWG2TA001080767_002
    Figure TWG2TA001080767_002
  • Figure TWG2TA001080767_003
    Figure TWG2TA001080767_003
Patent Text Reader

Abstract

Fatty acid synthase (FASN) plays a role in Non-alcoholic fatty liver disease (NAFLD), also known as Metabolic dysfunction-associated steatotic liver disease (MASLD). Hepatic DNL is increased in patients with metabolic syndrome and MASLD compared to healthy individuals, associated with increased intake of dietary sugars. FASN gene expression is elevated in liver biopsies from MASLD patients. Thus, FASN is an attractive therapeutic target for treating MASH by modulating the DNL pathway. The present invention relates to carboxylic acid and ester compounds useful as inhibitors of FASN and methods for their preparation and use for treatment and prevention of above mentioned liver diseases.
Need to check novelty before this filing date? Find Prior Art